Denmark to cancel Johnson & Johnson coronavirus vaccine rollout, besides on voluntary foundation – experiences

Denmark won’t embrace Johnson & Johnson’s vaccine in its Covid immunization program over blood-clot issues, in keeping with media experiences. Authorities in Denmark are being further cautious and excluding AstraZeneca’s vaccine too.

A number of native media retailers reported the information on Monday, citing unnamed sources. 

Johnson & Johnson’s shot was quickly suspended within the US and EU final month amid experiences that quite a lot of folks developed uncommon blood clots after taking the jab. Deliveries on each side of the Atlantic have since resumed, aside from within the UK, which by no means accepted the vaccine within the first place.

Learn extra

Danish authorities have opted for a extra cautious path, though Reuters reported that excluding J&J’s shot might considerably delay the nation’s vaccination efforts.

Danish drug officers final month deserted using AstraZeneca’s Covid-19 vaccine, additionally citing the danger of blood clots. In March, Denmark turned the primary nation on this planet to quickly droop the AstraZeneca shot, however not like its European neighbors, the nation made that suspension everlasting.  

After the AstraZeneca ban, the World Well being Group said that Danish authorities have been exploring delivery unused doses to poorer nations, regardless of flagging the vaccine as having a “actual danger of extreme unwanted side effects.”

Denmark started vaccinations in December, and by the start of this 12 months had accepted 4 vaccines – from AstraZeneca, Johnson & Johnson, Moderna and Pfizer/BioNTech. With the most recent cancellation, Danes could now avail themselves solely of the Moderna or Pfizer/BioNTech photographs.

Although AstraZeneca and Johnson & Johnson have each been excluded from the nationwide vaccination program, Danish newspaper Ekstra Bladet reported afterward Monday that voluntary use of each jabs might be permitted.

Suppose your mates would have an interest? Share this story!

Source link

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button